Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Rhea-AI Summary
Alpha Cognition (NASDAQ: ACOG) was the subject of an updated coverage report by Stonegate Capital Partners following 2Q26 results that support the ongoing launch of ZUNVEYL. Net product revenue rose 71% quarter-over-quarter to $6.0 million, driven by a 37% increase in bottles dispensed to 8,294, with June reaching 2,997 bottles, the strongest month since launch. Stonegate notes there was no material stocking benefit and downstream PBM implementation remained at about 16%.
Prescriber and facility adoption expanded, with 1,347 quarterly prescribers, 1,024 repeat prescribers, 1,908 cumulative writers and 1,095 long-term care facilities generating prescriptions. Alpha Cognition lowered FY26 R&D and SG&A guidance to $50–$54 million while maintaining its 2027 operating profitability target. According to the company, CONVERGE data are expected in 3Q26, RESOLVE is underway and the sublingual program depends on comparative PK results, creating several upcoming milestones.
Positive
- Net product revenue +71% q/q to $6.0M in 2Q26
- Bottles dispensed +37% q/q to 8,294; June reached 2,997 bottles
- Broadening adoption with 1,347 quarterly prescribers and 1,095 LTC facilities
- High repeat utilization with 1,024 repeat prescribers and 1,908 cumulative writers
- Lower FY26 operating expense guidance for R&D and SG&A to $50M–$54M
- 2027 operating profitability target maintained despite adjusted FY26 spending
Negative
- Downstream PBM implementation remains low at approximately 16%, limiting payer access
- ZUNVEYL growth continues despite slower payer implementation, highlighting ongoing access constraints
- Sublingual program progress remains gated by comparative PK results, adding development dependency
Market reaction after 2Q26 guidance update: ACOG -6.05%
Following this news, ACOG has declined 6.05%, reflecting a notable negative market reaction. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $8.30. Trading volume is exceptionally heavy at 5.8x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | 2Q26 earnings report | Positive | +2.4% | ZUNVEYL revenue increased 71% quarter-over-quarter alongside prescription and facility growth. |
| Aug 03 | Earnings date notice | Neutral | +1.8% | Company scheduled its second-quarter results and business update for August 13. |
| Jul 29 | European patent grant | Positive | +4.6% | European patent covered benzgalantamine formulations and medical-use claims through 2042. |
| Jul 10 | Investor conference panel | Neutral | -1.3% | Chief executive was scheduled to participate in a late-stage commercial CNS panel. |
| Jun 23 | Board leadership change | Neutral | -2.7% | Dr. Robert Wills was elected chairman, succeeding retiring chair Len Mertz. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive company news in the available record was followed by gains, while neutral event and leadership notices were followed by declines.
Key Terms
formulary medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation. Net product revenue increased
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- ZUNVEYL demand continued to scale in 2Q26, with net product revenue increasing
71% q/q to$6.0M as bottles dispensed increased37% to 8,294 and June reached 2,997 bottles, the strongest month since launch. The absence of material stocking or additional formulary wins supports the view that the quarter was driven primarily by underlying demand and improving commercial execution. - Adoption is broadening while repeat utilization is deepening, with 1,347 quarterly prescribers, 1,024 repeat prescribers, 1,908 cumulative writers and 1,095 LTC facilities generating prescriptions during the quarter. With downstream PBM implementation still approximately
16% , we believe continued prescriber and facility productivity provides a meaningful growth path while broader payer access remains an additional potential driver. - Alpha Cognition continues to balance commercial investment with a growing evidence base, lowering FY26 R&D and SG&A guidance to
$50M -$54M while maintaining its 2027 operating profitability target. CONVERGE data are expected in 3Q26, RESOLVE is underway and the sublingual program remains gated by comparative PK results, providing several potential milestones as the Company works toward greater operating leverage.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309918